Latest News for: shigella

Edit

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 (Form 6-K) (Valneva SE)

Public Technologies 09 Apr 2025
) Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 ... NCT06615375), in approximately 120 healthy Shigella-naïve participants aged 18 to 50 years3.
  • 1
×